Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085411 | 0.89 | KDM4C (0.57) | KDM4CHSD11B1DPP4DPP8KDM5B | |
| SCHEMBL4083519 | 0.89 | NSD2 (0.56) | KDM4CHSD11B1DPP4DPP8KDM5B | |
| SCHEMBL16034143 | 0.78 | KDM4C (0.64) | KDM4CDPP4DPP8KDM5BNSD2 | |
| SCHEMBL16034475 | 0.77 | KDM4C (1.00) | KDM4CKDM5BKDM2B | |
| SCHEMBL4562976 | 0.76 | KDM4C (0.51) | KDM4CHSD11B1KDM5BNSD2KDM2B | |
| SCHEMBL4076257 | 0.73 | DPP4 (0.49) | HSD11B1DPP4DPP8NSD2CNR1 | |
| SCHEMBL14996667 | 0.70 | HSD11B1 (0.53) | HSD11B1DPP4CRHR1 | |
| SCHEMBL14996575 | 0.70 | HSD11B1 (0.53) | HSD11B1CRHR1 | |
| SCHEMBL4075928 | 0.70 | DPP4 (0.49) | HSD11B1DPP4DPP8 | |
| SCHEMBL6345578 | 0.69 | F2RL3 (0.52) | KDM4CHSD11B1DPP4DPP8F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | KDM4C 3003/4885HSD11B1 4190/4885DPP4 3477/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | KDM4C 3003/4885HSD11B1 4190/4885DPP4 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.